Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron^® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -